Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 6/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100515 | 0.97 | LRRK2 (0.41) | LRRK2MAPK1FGFR1FGFR2FGFR3 | |
| SCHEMBL10100656 | 0.96 | LRRK2 (0.40) | LRRK2MAPK1FGFR1FGFR2FGFR3 | |
| SCHEMBL10100393 | 0.90 | LRRK2 (0.38) | LRRK2MAPK1FGFR1FGFR2FGFR3 | |
| SCHEMBL10100390 | 0.90 | LRRK2 (0.45) | LRRK2MAPK1METFYN | |
| SCHEMBL10100468 | 0.89 | LRRK2 (0.41) | LRRK2MAPK1FGFR1FGFR2FGFR3 | |
| SCHEMBL10100389 | 0.89 | LRRK2 (0.41) | LRRK2MAPK1FGFR1FGFR2FGFR3 | |
| SCHEMBL10100392 | 0.88 | JAK2 (0.38) | LRRK2MAPK1FGFR1FGFR2FGFR3 | |
| SCHEMBL10100397 | 0.88 | LRRK2 (0.35) | LRRK2MAPK1FGFR1FGFR2FGFR3 | |
| SCHEMBL10100584 | 0.88 | FYN (0.41) | MAP4K4FYN | |
| SCHEMBL10100677 | 0.88 | LRRK2 (0.40) | LRRK2MAPK1FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2350045-A1 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | LRRK2 856/4885MAPK1 357/4885FGFR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.